<abstract xmlns="http://www.w3.org/1999/xhtml"><sec id="j_raon-2018-0037_s_006_w2aab3b7b4b1b6b1aab1c18b1Aa"><h3>Background</h3><p>Uncommon response during immunotherapy is a new challenging issue in oncology practice. Recently, new criteria for evaluation of response to immunotherapy <italic>immune response evaluation criteria in solid tumors</italic> (iRECIST) were accepted. According to iRECIST, worsening of performance status (PS) accompanied to pseudoprogression reflects most probably the true progression of the malignant disease.</p></sec><sec id="j_raon-2018-0037_s_007_w2aab3b7b4b1b6b1aab1c18b2Aa"><h3>Methods</h3><p>A systematic review of the literature was made by using several electronic database with the following search criteria: symptomatic pseudoprogression, atypical response, immunotherapy and lung cancer.</p></sec><sec id="j_raon-2018-0037_s_008_w2aab3b7b4b1b6b1aab1c18b3Aa"><h3>Results</h3><p>In the literature, we identified five reports of seven patients treated with immunotherapy that met the inclusion criteria. We also report our experience of patient with pseudoprogression and almost complete response after one dose of immunotherapy.</p></sec><sec id="j_raon-2018-0037_s_009_w2aab3b7b4b1b6b1aab1c18b4Aa"><h3>Conclusions</h3><p>As seen from our review, iRECIST criteria might be insufficient in distinguishing true progression from pseudoprogression in some patients with advanced NSCLC treated with immunotherapy. More precise assessment methods are urgently needed.</p></sec></abstract>

BackgroundUncommon response during immunotherapy is a new challenging issue in oncology practice. Recently, new criteria for evaluation of response to immunotherapy immune response evaluation criteria in solid tumors (iRECIST) were accepted. According to iRECIST, worsening of performance status (PS) accompanied to pseudoprogression reflects most probably the true progression of the malignant disease.MethodsA systematic review of the literature was made by using several electronic database with the following search criteria: symptomatic pseudoprogression, atypical response, immunotherapy and lung cancer.ResultsIn the literature, we identified five reports of seven patients treated with immunotherapy that met the inclusion criteria. We also report our experience of patient with pseudoprogression and almost complete response after one dose of immunotherapy.ConclusionsAs seen from our review, iRECIST criteria might be insufficient in distinguishing true progression from pseudoprogression in some patients with advanced NSCLC treated with immunotherapy. More precise assessment methods are urgently needed.

Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy

Radiology and Oncology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

BackgroundUncommon response during immunotherapy is a new challenging issue in oncology practice. Recently, new criteria for evaluation of response to...

Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy

Article Category: Research Article

Publicado en línea: 18 oct 2018

Páginas: 365 - 369

Recibido: 05 feb 2018

Aceptado: 12 mar 2018

DOI: https://doi.org/10.2478/raon-2018-0037

Palabras clave
symptomatic pseudoprogression, atypical response, immunotherapy, lung cancer

© 2018 Martina Vrankar, Mojca Unk, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy

Article Category: Research Article

Publicado en línea: 18 oct 2018

Páginas: 365 - 369

Recibido: 05 feb 2018

Aceptado: 12 mar 2018

DOI: https://doi.org/10.2478/raon-2018-0037

Palabras clavesymptomatic pseudoprogression, atypical response, immunotherapy, lung cancer

© 2018 Martina Vrankar, Mojca Unk, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Palabras clave
symptomatic pseudoprogression, atypical response, immunotherapy, lung cancer